B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

CHUK

MOLECULAR TARGET

component of inhibitor of nuclear factor kappa B kinase complex

UniProt: O15111NCBI Gene: 114718 compounds

CHUK (component of inhibitor of nuclear factor kappa B kinase complex) is targeted by 18 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting CHUK

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1foretinib4.3476
2pi 1034.1764
3midostaurin3.8546
4norharmane3.7642
5nintedanib3.6136
6fedratinib3.4029
7dovitinib3.0921
8lestaurtinib3.0420
9r 4062.8316
10imd 03542.8316
11bms 3455412.7114
12kw 24492.6413
13ast 4872.5612
14as 6028682.5612
15su 0148132.208
16gsk 625137a1.795
17glaucarubinone1.102
18chicoric acid0.691

About CHUK as a Drug Target

CHUK (component of inhibitor of nuclear factor kappa B kinase complex) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 18 compounds with documented CHUK interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

CHUK inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.